2026-10-01 · Citizens Against Government Waste
Drug prices: Eric Maus on the real cost of government intervention
with Eric Maus, Director of Health and Science Policy — Citizens Against Government Waste

Government programs such as Medicare Part D and 340B were meant to lower drug prices but have often increased costs for patients, says Eric Maus, director of health and science policy at Citizens Against Government Waste. He highlights the significant costs associated with programs like Medicare Part D and the 340B program, revealing that despite intentions to lower prices, such interventions have often led to increased costs for patients. Maus also addresses proposed legislation aimed at modernizing drug information delivery, emphasizing the need for a more efficient and cost-effective approach in healthcare policy.
Related coverage
Drug Prices: The Real Cost of Government Intervention
Drug Prices: The Real Cost of Government Intervention
In a recent episode of the Health Policy Podcast, Eric Maus, Director of Health and Science Policy at Citizens Against Government Waste, discussed the impact of government intervention on drug prices in the United States. The conversation, hosted by Bryan Hyde, touched on various aspects of drug pricing, including the 340B program, Medicare Part D, and proposed legislation aimed at modernizing prescription information.
Maus emphasized the sheer scale of spending on prescription drugs in the U.S., estimating that it amounts to hundreds of billions or even trillions of dollars annually when considering private insurance and government programs like Medicare and Medicaid. He noted that the 340B program, designed to provide discounted drugs to certain healthcare providers, has seen its purchases exceed $100 billion for the first time in 2025. This program, established in 1992, was intended to help uninsured patients but has faced criticism for its broad interpretation and lack of oversight.
The discussion also highlighted the Inflation Reduction Act, which includes provisions allowing the government to set prices on select drugs. Maus pointed out that the Congressional Budget Office initially estimated that these price controls would save $129 billion from 2022 to 2031. However, recent updates indicate that the actual cost could reach $700 billion, with drug prices rising instead of falling. "Throughout history, price controls, especially on medication, have been found to increase prices and limit access to these medicines," Maus said.
Maus explained that lawmakers from both parties have pushed for price controls, driven by public concern over healthcare costs. He argued that pharmaceutical companies would generally prefer a free-market approach, as the development of new drugs is a costly and uncertain endeavor. He cited the European Union's more interventionist policies as a cautionary tale, noting that the U.S. has become a leader in drug development partly due to its more market-friendly environment.
The conversation shifted to a new piece of legislation introduced by Senators Cory Booker and Jim Banks aimed at modernizing the process by which drug manufacturers provide prescribing information. The Prescription Information Modernization Act of 2026 seeks to replace outdated paper-based systems with electronic communication, allowing healthcare providers to access updated information more quickly. Maus highlighted the inefficiencies of the current system, where information can take months to be processed and often becomes obsolete by the time it reaches providers.
Maus noted that while the bill is still in its early stages, there has been no significant opposition thus far. He expressed optimism that the modernization of this process could save pharmaceutical companies time and money, although the direct impact on taxpayers remains unclear.
In conclusion, Maus urged listeners to remain vigilant about government actions that claim to address drug pricing issues. He cautioned that while lawmakers may tout solutions, the outcomes often do not align with expectations. "When you see stuff coming out of Washington claiming to solve X, Y, or Z problem, oftentimes the reality doesn't match up," he said.
The full episode of the Health Policy Podcast featuring Eric Maus can be accessed on various podcast platforms, and more information about Citizens Against Government Waste is available at CAGW.org.
Interview Q&A
Q&A: Drug Prices: The Real Cost of Government Intervention
Drug Prices: The Real Cost of Government Intervention
Q: Can you tell us about your background and your role at Citizens Against Government Waste?
A: My name is Eric Maus. I'm the Director of Health and Science Policy for Citizens Against Government Waste, a taxpayer advocacy group founded in 1984. We focus on reducing government waste and inefficiencies.
Q: How much is spent on prescription drugs in America annually?
A: It's likely hundreds of billions or even trillions of dollars, including private insurance and government programs like Medicare and Medicaid. Drug prices are a significant concern for many Americans.
Q: What can you tell us about the 340B program?
A: The 340B program, administered by the Health Resources and Services Administration, exceeded $100 billion in purchases in 2025. It was intended to help uninsured patients access affordable drugs, but a lack of oversight has led to significant growth and misuse of the program.
Q: What is Medicare Part D, and how does it relate to drug pricing?
A: Medicare Part D is another large program. The Inflation Reduction Act of 2022 allowed the government to set prices on select drugs, which was initially projected to save $129 billion but is now estimated to cost $700 billion. Drug prices have increased since the law was enacted.
Q: Why do you think lawmakers are not acknowledging the failures of these measures?
A: Lawmakers often claim victory in reducing drug prices, even when the reality shows otherwise. They may be reluctant to admit that price controls have not worked as intended.
Q: Who advocates for price controls on drugs?
A: Price controls are pushed by lawmakers from both parties, primarily Democrats, but some Republicans as well. The populist message around healthcare costs drives this initiative.
Q: Do pharmaceutical companies prefer more government intervention or a free market approach?
A: Pharmaceutical companies generally prefer a free market approach. Developing drugs is costly, and they benefit from a system that encourages innovation and competition.
Q: Are there any lawmakers working to roll back government intervention in drug pricing?
A: Yes, many elected Republicans in both the House and Senate are advocating for a more market-friendly approach to drug pricing.
Q: What is the Prescription Information Modernization Act of 2026?
A: This bill, introduced by Senators Cory Booker and Jim Banks, aims to modernize the process of sending prescribing information electronically instead of on paper, which is outdated and inefficient.
Q: What changes does the Prescription Information Modernization Act propose?
A: The bill seeks to remove the 1962 regulation requiring paper distribution of prescribing information. It allows drug manufacturers to send this information electronically, making it more timely and accessible.
Q: Has there been any opposition to the Prescription Information Modernization Act?
A: There has been no notable opposition so far, but it is still early in the legislative process.
Q: Would modernizing the prescribing information process save costs?
A: While it would save pharmaceutical companies time and money, the impact on taxpayer savings is less clear. However, it would reduce waste and improve efficiency.
Q: What is the key takeaway regarding government intervention in drug pricing?
A: Government measures often promise solutions but fail to deliver. It's essential for taxpayers to be aware of how these policies can lead to waste and inefficiencies in the healthcare system.
Key questions
What is Citizens Against Government Waste?
Citizens Against Government Waste is a taxpayer advocacy group founded in 1984, aimed at identifying and reducing wasteful government spending.
How much is spent on prescription drugs in America?
The spending on prescription drugs in America is in the hundreds of billions or even trillions of dollars annually, including private insurance and government programs like Medicare and Medicaid.
What is the 340B program?
The 340B program is designed to provide discounted drugs to federally funded clinics that serve uninsured patients, but it has grown significantly due to a lack of oversight.
What changes were made in the Inflation Reduction Act regarding drug prices?
The Inflation Reduction Act allows the government to set prices on select drugs, but it has led to increased costs rather than savings, raising monthly drug prices instead of lowering them.
What is the Prescription Information Modernization Act of 2026?
The Prescription Information Modernization Act of 2026 aims to modernize the way drug manufacturers send prescribing information to healthcare providers, allowing for electronic delivery instead of paper.
What are the benefits of modernizing prescribing information?
Modernizing prescribing information will save time and resources, reduce waste, and ensure healthcare providers have access to the most up-to-date information.
Are there any lawmakers advocating for a free market approach in drug pricing?
Yes, many lawmakers, particularly Republicans, are advocating for a free market approach to drug pricing, arguing that less government intervention would lead to better outcomes.
How can taxpayers be affected by drug pricing policies?
Taxpayer money is often used to fund government programs that may be inefficient or wasteful, which can lead to higher costs for everyone, especially as drug prices rise.
Key takeaways
- “Prices are kind of a main concern for people across the board, but especially in healthcare and with prescription drugs.”
- “Throughout history, price controls, especially on medication, have been found to increase prices and limit access to these medicines.”
- “I think it's safe to say that they would prefer a more free market approach.”
- “Washington and lawmakers tend to deliver big and the results don't match it and don't deliver.”
- “It's important to remember that while these issues may seem kind of abstract or in the weeds, it affects everybody who's a taxpayer.”
- “These companies invest a lot in research and development and manufacturing.”
About the guest
Director of Health and Science Policy — Citizens Against Government Waste
Eric Maus is director of health and science policy at Citizens Against Government Waste.
Full transcript
Show full transcriptHide transcript
Filed under
